arrow
G

Giulia Siravegna

Colorado State University System
H指数:48
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

在BRAFV600E结直肠癌中联合PD-1,BRAF和MEK抑制: 一项2期试验

2023-01-2678
OAAI
Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer

人乳头瘤病毒相关口咽癌手术后的无细胞人乳头瘤病毒DNA动力学

CANCER
IF5.1
2022-02-0949
OAAI
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
2021-04-2961
OA
Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation

通过新型KRAS Switch-II口袋突变和融合ras-mapk再激活的多克隆改变对KRASG12C抑制的临床获得性抗性

2021-04-06308
OA
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer
2020-12-0173
OAAI
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (vol 25, pg 1415, 2019)

液体与组织活检用于检测胃肠癌的获得性耐药性和肿瘤异质性 (第25卷,1415页,2019)

2019-11-192
OAAI
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

液体与组织活检用于检测胃肠道癌症的获得性耐药性和肿瘤异质性

2019-09-09361
OAAI
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
2019-08-01293
OAAI
Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers
2019-07-010
PRE
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer
2019-07-010
PRE
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology

用于结直肠癌精确肿瘤学的基因组分析工作流程

2019-06-0125
PREAI
Multisite analysis of high-grade serous epithelial ovarian cancers identifies genomic regions of focal and recurrent copy number alteration in 3q26.2 and 8q24.3
2019-04-2616
OAAI